• Early HR+/HER2- disease: chemo benefit seen even with midrange recurrence scores

    This study is the first to examine chemo benefit in this recurrence score range.

  • NICE recommends trastuzumab emtansine for early breast cancer
    NICE recommends trastuzumab emtansine for early breast cancer

    The drug was earlier approved for HER2-positive secondary breast cancer.

  • Early TNBC: PARP1 polymorphism is linked to better DFS

    None of the polymorphisms influenced OS or treatment toxicities.

  • Breast cancer: predicting lymphoedema and quality of life deficits after axillary surgery

    Research led by Manchester University NHS Foundation Trust

  • Early breast cancer: 5-year data show 1-week RT as safe, effective as standard 3 weeks

    FAST-Forward UK noninferiority trial tested 4096 patients at 97 hospitals.

  • AACR 2020 – Advanced breast cancer with germline BRCA mutation: no OS benefit with talazoparib

    Final analysis of the EMBRACA trial.

  • AACR 2020 – Immunotherapy combo boosts response in HER2- breast cancer

    Responses improved in TNBC and HR+ subtypes

  • Potential impact of male mammographers on breast cancer screening rates
    Potential impact of male mammographers on breast cancer screening rates

    Almost a third of eligible women would not attend for screening if the mammographer was male.

  • Breast cancer: high MST1R (RON) may be prognostic for metastatic progression, survival

    MST1R is unrelated to tumor stage, nodal status, or subtype.

  • Breast cancer risk: modifiable vs genetic factors

    A study of more than 90,000 women using data from the UK Biobank

  • Denosumab: best bone-modifying agent in setting of HR+ breast cancer and AIs?

    Network meta-analysis finds denosumab increases BMD and decreases fracture risk.

  • AACR 2020 - Systematic analysis of BRAF mutations can identify patients sensitive to BRAF inhibitors

    Functional annotation of novel variants through high throughput method is crucial for assigning correct treatment

  • Breast cancer: RT-related pain peaks at 1 week after treatment ends

    Nearly 80% of the Canadian cohort reports breast pain at its peak.

  • Mammography screening decision aid for older women may cut overscreening

    Findings based on a cluster randomized trial of 546 women in primary care.

  • Load more